Showing 20 of 84 recruiting trials for “non-hodgkin-lymphoma”
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
👨⚕️ Grzegorz S Nowakowski, Academic and Community Cancer Research United📍 6 sites📅 Started Jan 2024View details ↗
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
👨⚕️ Wei Liu, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC📍 1 site📅 Started Jan 2024View details ↗
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
👨⚕️ Yuqin Song, M.D, Peking University Cancer Hospital & Institute📍 1 site📅 Started Dec 2023View details ↗
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
RecruitingNCT05705531 ↗
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
👨⚕️ David A Bond, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Jun 2023View details ↗
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
👨⚕️ Ramya M Ramaswami, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Jun 2023View details ↗
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
👨⚕️ Konstantinos Christofyllakis, MD MSc, Saarland University Medical Center📍 17 sites📅 Started Jun 2023View details ↗
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Study of LYL314 in Aggressive Large B-Cell Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
👨⚕️ Yuankai Shi, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started May 2023View details ↗
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
👨⚕️ Jason Westin, MD, MS, FACP, M.D. Anderson Cancer Center📍 1 site📅 Started Apr 2023View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →